Novo Nordisk-backed biopharmaceutical company MapLight files for US IPO

2025-09-20 07:57:24

On September 19th, local time, MapLight Therapeutics, a clinical-stage biopharmaceutical company backed by Novo Nordisk, filed for an IPO in the United States. The filing shows that the company's lead product candidates include two drugs for the treatment of schizophrenia and Alzheimer's disease psychotic disorder (ADP).

Novo Nordisk

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Musk: XAI will certainly raise funds in the next few months, but not now
                            2025-09-20

                                    Nvidia (NVDA.O) fell further, dropping nearly 3%.
                            2025-09-17

                                    SoftBank and OpenAI's AI joint venture in Japan is severely delayed, with an update now expected in November.
                            2025-09-18

                                    HGTECH's 3.2T NPO products are used by leading industry customers
                            2025-09-24

                                    Alipay's two operating entities have completed the name change
                            2025-09-19